NEW YORK, August 3, 2017 /PRNewswire/ --
If you want a Stock Review on ALGN, IVC, GMED, or RMD then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has initiated research coverage on Align Technology Inc. (NASDAQ: ALGN), Invacare Corp. (NYSE: IVC), Globus Medical Inc. (NYSE: GMED),
San Jose, California headquartered Align Technology Inc.'s stock finished Wednesday's session 0.85% lower at $167.99 with a total trading volume of 725,790 shares. Over the last month and the previous three months, the Company's shares have advanced 12.72% and 27.29%, respectively. Additionally, the stock has surged 74.75% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 11.20% and 45.15%, respectively. Moreover, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services, have a Relative Strength Index (RSI) of 63.66.
On July 10th, 2017, Align Technology unveiled a new company logo that unifies its product brands under one brand umbrella. The new logo is based on the Company's name, "Align" Technology, and complements the new Invisalign brand identity that was launched earlier this year. The bold new redesign represents a clean, fresh, sophisticated, and contemporary feel that elevates the Company brand to better represent the innovative spirit in which its products are conceived.
On July 28th, 2017, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'. Your complete research report on ALGN can be retrieved for free at:
Shares in Elyria, Ohio headquartered Invacare Corp. declined 1.28%, ending yesterday's session at $15.45 with a total trading volume of 441,217 shares. The stock has gained 18.85% in the past month, 6.55% in the previous three months, and 18.39% on an YTD basis. The Company's shares are trading 14.50% above their 50-day moving average and 24.33% above their 200-day moving average. Moreover, shares of Invacare, which together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide, have an RSI of 60.96.
On July 25th, 2017, Invacare has received notice from the US Food and Drug Administration that it has successfully satisfied the agency's requirements under the consent decree to resume full operations at its Corporate and Taylor Street manufacturing facility in Elyria, Ohio. The Company is now able to produce and sell all products made in the Taylor Street facility without the previous restrictions under the consent decree, which has been in effect since December 21st, 2012. A free report on IVC is just a click away at:
On Wednesday, Audubon, Pennsylvania headquartered Globus Medical Inc.'s stock saw a slight drop of 0.94%, to close the day at $30.56. A total volume of 652,769 shares was traded, which was above their three months average volume of 505,780 shares. The Company's shares have advanced 23.18% on an YTD basis. The stock is trading 9.70% above its 200-day moving average. Additionally, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have an RSI of 34.48. Sign up for your complimentary research report on GMED at:
Shares in San Diego, California headquartered ResMed Inc. ended the day 6.41% lower at $72.51. A total volume of 4.36 million shares was traded, which was above their three months average volume of 1.17 million shares. The stock has gained 5.16% in the previous three months and 16.86% since the start of this year. The Company's shares are trading above their 200-day moving average by 5.89%. Furthermore, shares of ResMed, which designs, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases, have an RSI of 28.70.
On August 01st, 2017, ResMed announced results for its quarter ended June 30th, 2017. Revenue for the Q4 FY17 was $556.7 million, gross margin was 58.2%, income from operations was $127.4 million, and net income was $101.6 million. GAAP diluted earnings per share (EPS) for the quarter was $0.71, and non-GAAP diluted EPS was $0.77.
On August 02nd, 2017, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. Register for free on DailyStockTracker.com and download the latest research report on RMD at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All